Ascendis Pharma A/S (ASND) News Today

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Stock analysts at Leerink Partnrs dropped their Q3 2024 earnings per share (EPS) estimates for Ascendis Pharma A/S in a research report issued on Monday, September 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology compan

Seven Eight Capital LP lifted its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 245.4% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,876 shares of the biotechnology company's stock after buying an additional 11,279 shares

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 earnings estimates for Ascendis Pharma A/S in a research report issued to clients and investors on Monday, September 16th. Cantor Fitzgerald analyst L. Watsek now expects that the biotechnology co

Massachusetts Financial Services Co. MA grew its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 5.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,711,015 shares of the biotechn

Wells Fargo & Company raised their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a report on Tuesday.

Oppenheimer reiterated an "outperform" rating and issued a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday.

Sofinnova Investments Inc. lowered its position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 2.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 734,284 shares of the biotechnology company's stock after selling 19,748 sh

Ascendis Pharma A/S (NASDAQ:ASND) Shares Gap Up to $119.22

Cantor Fitzgerald restated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research note on Monday.

First Turn Management LLC raised its position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 23.1% during the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 186,581 shares of the biotechnology company's stock after acquiring an additional

Ascendis Pharma A/S (NASDAQ:ASND) Sees Large Volume Increase

Headlands Technologies LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 6,338 shares of the biotechnology com

Rice Hall James & Associates LLC reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 6.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 151,656 shares of the biotechnology company's sto

Acadian Asset Management LLC lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 43.2% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 142,165 shares of the b

Candriam S.C.A. raised its stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 96.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 195,347 shares of the biotechnology company's stock after acquiring an additional 95,972 shares

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Cantor Fitzgerald dropped their FY2024 earnings per share (EPS) estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Wednesday, September 4th. Cantor Fitzgerald analyst L. Watsek now anticipates that

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has earned an average recommendation of "Buy" from the fourteen research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, twelve have assigned a buy recommendatio

Ascendis Pharma A/S (NASDAQ:ASND) Stock Price Up 4.3% Following Analyst Upgrade

Citigroup reduced their price target on shares of Ascendis Pharma A/S from $193.00 to $178.00 and set a "buy" rating for the company in a research note on Wednesday.

JPMorgan Chase & Co. reduced their price target on Ascendis Pharma A/S from $174.00 to $165.00 and set an "overweight" rating for the company in a report on Wednesday.